m-Cresol

m-Cresol (3-methylphenol) is one of three cresol isomers produced industrially from petroleum fractions and coal tar. [1] It was historically used as a general disinfectant and antiseptic in hospital settings (Lysol's original formulation contained a mixture of cresol isomers). Its excellent antimicrobial properties at low concentrations and good solubility in injection preparations led to its adoption as a preservative in pharmaceutical parenteral (injectable) formulations. Today m-cresol is the most commonly used preservative in multiple-dose insulin vials — including many human insulin and insulin analog products. The concentration in pharmaceutical preparations (0.1–0.3%) is well below the threshold for significant systemic toxicity when injected subcutaneously in the small volumes used for insulin. [2] Industrial uses beyond pharmaceuticals include synthesis of cresyl glycidyl ethers (epoxy systems), pyrethroid insecticide synthesis (m-cresol is the phenol component of some pyrethroid alcohol precursors), and synthesis of specialty chemicals. m-Cresol is listed as a HAP under the Clean Air Act. Environmental releases come from petroleum refining, pharmaceutical manufacturing, and specialty chemical synthesis. Its metabolism and biomarker status are linked to toluene metabolism (see o-cresol), as both m- and p-cresol are minor toluene metabolites alongside the major o-cresol pathway. [3]

Chemical and pharmaceutical manufacturing workers have occupational inhalation and skin exposures. Diabetic patients who inject insulin from multi-dose vials or who use insulin pump systems are the largest population with regular parenteral m-cresol exposure, though systemic doses from insulin injection are very small. Researchers who handle m-cresol as a laboratory reagent face inhalation and skin exposures. Environmental background exposures from petroleum sources and tobacco smoke are low-level.

At industrial concentrations, m-cresol shares phenol's corrosive properties — it can cause serious skin and eye burns and is acutely toxic via all routes. [1] Systemic absorption causes liver and kidney damage. However, at pharmaceutical preservative concentrations, systemic toxicity from insulin injections is not considered clinically significant for most patients. Cases of injection site reactions in insulin users are occasionally attributed to the m-cresol component. In patients using insulin pumps with continuous subcutaneous infusion, cumulative m-cresol exposure from infusion sets that aren't changed frequently enough can cause local tissue effects. As an industrial chemical, chronic occupational exposures carry liver and kidney toxicity concerns.

Industrial chemical workers are at highest risk for significant exposures. Diabetic patients using multi-dose insulin vials have regular but very low-dose pharmaceutical exposures. Patients using continuous subcutaneous insulin infusion pumps with infrequently changed infusion sites may develop local reactions from m-cresol accumulation.

1. Industrial workers: local exhaust ventilation, chemical-resistant gloves, eye protection. 2. Insulin users: change infusion sites regularly as recommended (every 2–3 days for insulin pump users) to minimize local m-cresol accumulation. 3. Patients experiencing unexplained injection site reactions should discuss with their endocrinologist whether m-cresol sensitivity may be a factor. 4. m-Cresol-free insulin formulations (e.g., some insulin pens use phenol instead of m-cresol) may be considered for sensitive patients.